Biotechnology Company Deals With Other Biotechnology Companies: Collaborations, Agreements, Equity Participation, April 29 - June 23, 2004
Company* | Company* (Country; Symbol) | Type/Product Area | Terms/Details (Date) | |
Advanced Biotherapy Inc. (OTC BB:ADVB) | Innogenetics NV (Belgium; Euronext:INNX) | Agreement combining Innogenetics' humanized antibody to interferon-gamma (INNO 202) and ABI's interferon-gamma intellectual property | Proceeds from the cross-licensing deal will be shared; rheumatoid arthritis is their first target; both companies may continue to license their intellectual property rights to third parties (5/5) | |
Affymetrix Inc. (AFFX) | Immusol Inc.* | Immusol will use GeneChip technology to identify pathways from its engineered tumor cells in biological assays | Immusol seeks to discover and characterize new and existing targets for cancer therapies using the Affymetrix technology; terms were not disclosed (6/22) | |
Amphora Discovery Corp. | Caliper Life Sciences Inc. (CALP) | Caliper acquired cell culture techniques, as well as upgrades Amphora implemented on Caliper's microfluidic screening system | Amphora will get a combination of cash, Caliper products and royalties based on sales of cell-based assays (5/6) | |
Aptanomics SA* (France) | Nanosyn Inc.* | Aptanomics will use its peptide aptamer technology to screen Nanosyn's small-molecule libraries for cancer applications | Once hits are identified, Nanosyn will use its chemistry technologies to provide Aptanomics arrays of small molecules and other chemistry services; terms were not disclosed (5/4) | |
Avidex Ltd.* (UK) | Active Biotech AB (Sweden; SSE:ACTI) | Collaboration to create targeted immunotherapeutics for cancer using their protein molecule platforms | Active is contributing its superantigen protein and Avidex its platform of tumor antigen-specific human monoclonal T-cell receptors; terms were not disclosed (5/13) | |
Biomax Solutions Inc.* | Geospiza Inc.* | They will integrate and jointly sell their bioinformatics systems | Resulting products will be designed to turn DNA sequencing data into discovery information (6/9) | |
BioSpecifics Technologies Corp. (OTC BB: BSTC) | Auxilium Pharmaceuticals Inc.* | Auxilium licensed certain therapeutic applications for a BioSpecifics' enzyme | Auxilium will pay license fees and potential milestones and royalties, as well as a fee for manufacturing, in exchange for exclusive worldwide rights (6/7) | |
Cellectis SA* (France) | Murinus GmbH* (Germany) | Murinus got nonexclusive rights to use homologous recombination to replace or in- ert genes in the mouse genome | Murinus can develop and sell genetically modified mice in Europe and the Middle East under undisclosed terms (5/13) | |
Chiron Corp. (CHIR) | Prosetta Corp.* | Prosetta got nonexclusive rights for research and development related to certain hepatitis C virus drug targets | The deal is the first under which Chiron offers licenses that have no up-front or annual fees but could result in milestone and royalty payments (6/22) | |
Chiron Corp. (CHIR) | Oxford Biomedica plc (UK; LSE:OXB) | Oxford acquired certain rights to Chiron technology in the area of gene therapy | The technology complements Oxford programs in gene therapy; terms were not disclosed; separately, Chiron purchased 316,026 Oxford shares at 17.23 pence per share (6/7) | |
CombinatoRx Inc.* | Immtech International Inc. (AMEX:IMM) | CombinatoRx will screen Immtech aromatic cationic compounds DB289 and DB75 against various cancers | Terms of the deal were not disclosed (5/5) | |
Cytomyx Holdings plc (UK; LSE:CYX) | Paradigm Therapeutics Ltd.* (UK) | Deal to produce and sell mammalian cell lines containing the ion channel subunit SCN3B | Terms of the deal were not disclosed (5/5) | |
Cytomyx Holdings plc (UK; LSE:CYX) | CellFactors plc* (UK) | Deal to develop and sell human brain-derived cell lines that were created at CellFactors | Cytomyx will further validate 11 NeuCell lines and commercialize them worldwide; they would share revenues (4/20)# | |
Dyax Corp. (DYAX) | Genzyme Corp. (GENZ) | Genzyme got nonexclusive rights to antibody phage- display libraries for the discovery of human antibodies | Dyax gets an up-front license fee and potential milestones and royalties; Genzyme has an option to convert the license from research use to antibody development, and to fund research work by Dyax (6/2) | |
EiRx Therapeutics plc (Ireland; LSE:ERX) | OSI Pharmaceuticals Inc. (OSIP) | OSI exercised an option to license four apoptosis gene targets and move them into drug discovery in oncology | OSI for a year had been evaluating about 12 targets, and licensed four of them; EiRx gets up-front and consultancy fees, and potential success fees and milestones for each target (5/5) | |
Evotec OIA AG (Germany; FSE:EVT) | NeuroNova AG* (Germany) | Deal to identify small-molecule compounds that interact with a Neuronova target for depression and anxiety | Evotec will provide technologies and services to the collaboration, terms of which were not disclosed (6/14) | |
Evotec OIA AG (Germany; FSE:EVT) | Nuvios Inc.* | Evotec will screen small- molecule compounds for osteoporosis applications | The goal is to discover novel activators of bone anabolic activity; terms were not disclosed (5/19) | |
Evotec OIA AG (Germany; FSE:EVT) | Guilford Pharmaceuticals Inc. (GLFD) | Deal under which Evotec will identify small-molecule compounds that interact with certain Guilford targets | Evotec will get research fees and milestones based on successful preclinical development (5/13) | |
Formatech Inc.* | Mirus Therapeutics Corp.* | Mirus acquired formulation/ drug delivery technologies from Formatech | Mirus plans to develop improved formulations of existing drugs, and to partner the technology; terms of the deal were not disclosed (6/17) | |
4SC AG* (Germany) | Serono SA (Switzerland; NYSE:SRA) | Serono got exclusive worldwide rights to 4SC's program of small-molecule dihydroorotate dehydrogenase inhibitors for autoimmune diseases | 4SC gets an up-front payment, research funding and potential milestones that together could total $67M; it also would get royalties on sales; the deal includes the lead Phase I compound, SC12267 (5/4) | |
Genedata AG* (Switzerland) | MWG Biotech AG* (Germany) | Co-marketing agreement to offer functional genomics services for partners | The Genedata Phylosopher platform will be used with MWG products; terms of the deal were not disclosed (6/11) | |
Genentech Inc. (NYSE:DNA) | Tercica Inc. (TRCA) | Tercica gained rights to insulin- like growth factor-1 combined with insulin-like growth factor binding protein-3 | Tercica paid $1.3M in exercising its option; the exclusive license covers all indications outside of CNS disorders and is worldwide except for diabetes outside the U.S. (6/15) | |
Genzyme Corp. (GENZ) | Peptimmune Inc.* | Peptimmune licensed worldwide rights to GT389-255, a candidate for obesity and other metabolic disorders | Peptimmune plans to file an IND on the product later this year; it will pay Genzyme royalties on any sales and share payments from any partners for the drug (5/10) | |
Geron Corp. (GERN) | CXR Biosciences Ltd.* (UK) | Collaboration, along with the Roslin Institute, to develop human embryonic stem cell- derived hepatocytes | They will be used in in vitro assays of drug metabolism and toxicity; Geron and CXR would commercialize resulting products; terms were not disclosed (5/20) | |
GTx Inc. (GTXI) | DiaDexus Inc.* | GTx will provide clinical data from a trial of Acapodebe in men with high-grade prostatic intraepithelial neoplasia | DiaDexus will use the data to develop an assay or test to detect high-grade PIN and/or prostate cancer; terms were not disclosed (6/15) | |
Guilford Pharmaceuticals Inc. (GLFD) | Symphony Neuro Development Co.* | Symphony licensed U.S. rights to the neuroimmunophilin ligand GPI 1485 in Parkinson's disease and uses related to HIV and erectile dysfunction | SNDC investors got five-year warrants to purchase 1.5M Guilford shares at $7.48 per share; Guilford has an option to reacquire the product for $75.1M to $119.8M; SNDC was formed specifically for this deal (6/18) | |
Incyte Corp. (INCY) | Ingenium Pharmaceuticals AG* (Germany) | Ingenium acquired two patents related to genetic rat and mouse models | Ingenium previously had a license to the patents, Nos. 5,994,075 and 6,015,670; terms were not disclosed (5/12) | |
Intercell AG* (Germany) | Solvo Biotechnology Inc.* (Hungary) | Solvo got an exclusive license to develop a diagnostic product for detecting PIBF in human patient samples | The deal covers Intercell's progesterone-induced blocking factor technology; terms were not disclosed (6/23) | |
Juvaris BioTherapeutics Inc.* | SomaGenics Inc.* | Deal to combine RNA-based gene-inhibition technology of SomaGenics with Juvaris' immunomodulatory and vaccine technology | The initial focus is on developing a product that could be used to elicit both non-specific and specific protection against anthrax and anthrax toxin; terms were not disclosed (5/12) | |
Labopharm Inc. (Canada; TSE:DDS) | Debiopharm SA* (Switzerland) | Labopharm will research the potential oral delivery of a Debiopharm cancer drug | Labopharm will apply its nanodelivery systems technology (asmicelles technology) in the deal, terms of which were not disclosed (6/16) | |
Lantibio Inc.* | AOP Orphan Pharmaceuticals AG* (Austria) | AOP will assume control of developing Moli1901 in Europe for treating cystic fibrosis | Lantibio gets undisclosed up-front payments as well as potential milestones and royalties; AOP is planning a Phase II trial in Germany (5/26) | |
LGC Ltd.* (UK) | ChemOvation* (UK) | Collaboration to combine technologies in order to improve offerings to drug discovery companies | They will bring together ChemOvation's medicinal and organic chemistry and LGC's biomeasurement cell-based testing capabilities; terms were not disclosed (5/6) | |
Mimetix Inc.* | Symbollon Pharmaceuticals Inc. (OTC BB:SYMBA) | Symbollon acquired assets on iodine drug development, which it will use in its IoGen program | Symbollon issued 550,000 shares for the assets, which include trial data from women with fibrocystic breast condition treated with molecular iodine (6/14) | |
Mologen AG* (Germany) | MEBO International Group (China) | Agreement to develop comb- ination treatments against cancer | They will combine Mologen's fourfold immunomodulated tumor cells and MEBO's herbal extracts; they would file for joint patents on resulting products (4/27)# | |
Nautilus Biotech* (France) | Serono SA (Switzerland; NYSE:SRA) | Collaboration to develop therapeutic proteins with improved characteristics | Nautilus will design and validate protein variants; Serono would develop and market resulting products; terms of the deal were not disclosed (6/21) | |
Nektar Therapeutics (NKTR) | SciClone Pharmaceuticals Inc. (SCLN) | Deal to use Nektar technology to develop a pegylated form of Zadaxin | The SciClone product is being developed for treating hepatitis C; terms of the deal were not disclosed (5/26) | |
Orphan Therapeutics LLC* | ESP Pharma Inc.* | ESP acquired rights to intra- venous terlipressin, a drug in Phase III trials for Type I hepato-renal syndrome | ESP will make up-front and potential milestone and royalty payments in exchange for exclusive rights in the U.S. and Canada (6/8) | |
PamGene International BV* (the Netherlands) | Jerini Peptide Technologies (unit of Jerini AG*; Germany) | Collaboration to combine technologies to provide a new offering for kinase studies | The resulting product offering would have applications in signal transduction-focused research; terms of the deal were not disclosed (6/22) | |
PamGene International BV* (the Netherlands) | Innogenetics NV* (Belgium; Euronext:INNX) | Innogenetics gets access to PamGene's microarray tech- nology platform for the development of assays | PamGene gets an up-front payment, milestones as tests reach the market, and royalties on sales in exchange for the exclusive license to its PamStation 12 instrumentation in certain indications (5/27) | |
ProMetic Life Sciences Inc. (Canada; TSE:PLI) | Hemosol Inc. (Canada; TSE:HML) | Hemosol licensed plasma- separation technology developed by ProMetic and the American Red Cross | Hemosol issued 2M shares to ProMetic and will pay license fees of C$15.5M (US$11.3M) over four years, as well as issue another 1M shares; the cascade-purification technology is used to recover proteins from human plasma (6/2) | |
Prosidion Ltd. (UK unit of OSI Pharmaceuticals Inc.; OSIP) | Probiodrug AG* (Germany) | Prosidion purchased dipeptidyl peptidase IV technology, which is in Phase II trials for treating Type II diabetes | Probiodrug gets $35M in cash and potential development milestones; OSI is investing another $50M in Prosidion and will own 96% of the subsidiary (6/18) | |
ProteomTech Inc.* | Pivotal BioSciences Inc.* | ProteomTech will help Pivotal with protein expression and development processes for PB1 | The product is an analogue of interleukin-2; terms were not disclosed (5/5) | |
Raven Biotechnologies Inc.* | ICOS Corp. (ICOS) | ICOS got an exclusive option to license five Raven monoclonal antibody candidates with applications in cancer | Raven will receive an up-front payment as well as potential milestones and royalties on sales; further terms were not disclosed (6/9) | |
Seattle Genetics Inc. (SGEN) | CuraGen Corp. (CRGN) | CuraGen licensed antibody- drug conjugate technology for use with its antibodies in treating cancer | Seattle Genetics gets $2M up front and up to $28M in milestones if two products are developed; CuraGen also will pay other fees and would pay royalties on sales (6/22) | |
Senetek plc (SNTK) | Ardana Bioscience Ltd.* (UK) | Ardana will manufacture and market Senetek's Invicorp erectile dysfunction treatment in Europe | Ardana assumes all reponsibility in Europe for the injectable product; Senetek can earn regulatory and sales milestones, as well as royalties on sales (6/21) | |
SkyePharma plc (UK; SKYE) | Trigenesis Therapeutics Inc.* | SkyePharma licensed to Trigenesis dermatology assets that include residual rights to three marketed products, six pipeline products and various delivery technologies | SkyePharma gets up-front payments for each of the six development products, as well as potential milestones, which together could exceed $20M; it also would get 10% royalties and 35% of any sublicense fees (4/29) | |
Syntonix Pharmaceuticals Inc.* | Dyax Corp. (DYAX) | Collaboration to discover and develop antibodies for auto- immune and inflammatory disorders | Syntonix will provide assays, reagents and certain preclinical development work, and Dyax will screen for candidates using its antibody libraries; development and financial terms were not disclosed (5/13) | |
TopoTarget A/S* (Denmark) | CuraGen Corp. (CRGN) | Deal to develop TotoTarget's PXD101, a histone deacetylase inhibitor that is in Phase I trials for cancer indications | In exchange for worldwide rights excluding Europe, CuraGen is making a $5M equity investment and paying $5M in license fees, up to $14M over 36 months in milestones and research support, and up to $27M more in milestones; they would pay reciprocal sales royalties; CuraGen also got an option to additional HDAC compounds for which it would pay up to $1M in license fees and $30M in milestones per product (6/3) | |
Valentis Inc. (VLTS) | Juvaris BioTherapeutics Inc.* | Juvaris got exclusive rights to Valentis' plasmid backbone in conjunction with its DOTIM cationic lipid for use in therapeutic vaccines | Valentis will receive cash payments and be eligible for development milestones and royalties on sales (6/4) | |
Vectura Ltd.* (UK) | SkyePharma plc (UK; SKYE) | SkyePharma will use Vectura's Aspirair dry-powder inhaler for delivering certain macro- molecules | SkyePharma invested £2M (US$3.7M) in Vectura, or 4% of the company, for the non-exclusive rights; further terms were not disclosed (6/2) | |
ViroPharma Inc. (VPHM) | SIGA Technologies Inc. (SIGA) | SIGA is acquiring certain viral research programs targeting agents that could be used in biological warfare | ViroPharma gets $1M in cash and 1M SIGA shares; the targets include smallpox and hemorrhagic fever viruses (6/9) | |
Xerion Pharmaceuticals AG* (Germany) | Stemline Therapeutics Inc.* | Collaboration to identify novel protein targets expressed on cancer stem cells | They will share costs and revenues from the deal, under which they will apply Xerion's Xstream technology to Stemline's cancer stem cell platform (6/9) | |
XTL Biopharmaceuticals Ltd. (Israel; LSE:XTL) | Cubist Pharmaceuticals Inc. (CBST) | Worldwide license deal for XTL's Phase II product HepeX-B for preventing hepatitis B re-infection in liver transplant patients | Cubist will fund development and be responsible for sales; XTL will get collaboration support and $3M over two years, as well a potential $3M regulatory milestone payment and 10% to 17% on net sales (6/3) | |
ZymoGenetics Inc. (ZGEN) | Amgen Inc. (AMGN) | Amgen got exclusive world- wide rights to ZymoGenetics' patents covering a metabolic disease target | Amgen is purchasing $10M of ZymoGenetics stock, as well as paying an up- front license fee and potential downstream consideration (5/20) | |
Notes: | ||||
* Private companies are indicated with an asterisk. | ||||
# Item occurred before April 20 but was not included in the previous chart. | ||||
Unless otherwise noted, the trading symbols listed for public biotechnology companies are on the Nasdaq market. | ||||
FSE = Frankfurt Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange. | ||||